Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study.

Wei Zhang,Yanhong Tan,Jun Ai,Fuzhang Luo,Xiaoyan Su,Qimeng Wu,Lijuan Su,Jianyi Pan,Qingkun Zheng,Bin Li,Jiayi Chen,Qimei Luo,Jinzhong Chen,Xianrui Dou

Annals of translational medicine（2022）

引用 0|浏览9

暂无评分

摘要

Our study demonstrated that compared with rhuEPO, roxadustat may reduce the risk of PD-associated peritonitis in PD patients, highlighting the importance of roxadustat for the prevention of PD-associated peritonitis in PD patients.

查看译文

关键词

Roxadustat,peritoneal dialysis (PD),peritoneal dialysis-associated peritonitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要